[1]翟改霞,王少鹏,苏元镇,等.玻璃体内注射康柏西普治疗特发性脉络膜新生血管[J].眼科新进展,2020,40(1):066-69.[doi:10.13389/j.cnki.rao.2020.0016]
 ZHAI Gaixia,WANG Shaopeng,SU Yuanzhen,et al.Effect of intravitreal Conbercept for idiopathic choroidal neovascularization[J].Recent Advances in Ophthalmology,2020,40(1):066-69.[doi:10.13389/j.cnki.rao.2020.0016]
点击复制

玻璃体内注射康柏西普治疗特发性脉络膜新生血管/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年1期
页码:
066-69
栏目:
应用研究
出版日期:
2020-01-05

文章信息/Info

Title:
Effect of intravitreal Conbercept for idiopathic choroidal neovascularization
文章编号:
20200116
作者:
翟改霞王少鹏苏元镇王作芬信兆亭
255000 山东省淄博市,淄博市中心医院眼科(翟改霞,王少鹏,王作芬,信兆亭);255000 山东省淄博市,淄博市中心医院心内科(苏元镇)
Author(s):
ZHAI Gaixia1WANG Shaopeng1SU Yuanzhen2WANG Zuofen1XIN Zhaoting1
1.Department of Ophthalmology,Zibo Central Hospital,Zibo 255000,Shandong Province,China
2.Department of Cardiology,Zibo Central Hospital,Zibo 255000,Shandong Province,China
Corresponding author:WANG Shaopeng,E-mail:904268100@ qq.com
关键词:
康柏西普特发性脉络膜新生血管血管内皮生长因子
Keywords:
Conberceptidiopathic choroidal neovascularizationVEGF
分类号:
R773.4
DOI:
10.13389/j.cnki.rao.2020.0016
文献标志码:
A
摘要:
目的 观察玻璃体内注射康柏西普治疗特发性脉络膜新生血管(idiopathic choroidal neovascularization,ICNV)的临床疗效。方法 对2015年6月至2017年10月于我院确诊并行玻璃体内注射0.05 mL(0.5 mg)康柏西普治疗的20例20眼ICNV患者的临床资料进行回顾性分析,所有患者均采用1+PRN治疗策略,第1次随访时间为首次注射后1周,以后每月随访1次,均完成6个月的随访。记录CNV病灶渗漏情况、最佳矫正视力(best corrected visual acuity,BCVA)、黄斑中心凹视网膜厚度(central macular retinal thickness,CRT)、眼部及全身不良反应等。结果 20眼中,玻璃体内注射1~3(1.60±0.68)次,其中注射1次者10眼,注射2次者8眼,注射3次者2眼。治疗前BCVA为(55.15±6.82)个字母数,治疗后1周、1个月、3个月、6个月分别为(61.50±6.16)个字母数、(71.00±5.10)个字母数、(73.90±6.75)个字母数、(77.95±5.12)个字母数,治疗前患者CRT为(342.75±36.39)μm,治疗后1周、1个月、3个月、6个月分别为(301.15±32.16)μm、(231.85±30.25)μm、(240.05±56.99)μm、(229.75±48.18)μm,治疗后各时间点BCVA及CRT与治疗前相比差异均有统计学意义(均为P<0.05)。随访6个月时,17眼病灶渗漏停止,3眼病灶渗漏面积明显缩小,20眼均未出现新的病灶。所有患眼在随访期间均未发生青光眼、眼内炎、白内障进展、视网膜脱离等眼部严重并发症或全身不良反应。结论 玻璃体内注射康柏西普治疗ICNV安全有效。
Abstract:
Objective To observe the clinical efficacy of intravitreal Conbercept in the treatment of idiopathic choroidal neovascularization (ICNV).Methods Retrospective analysis was conducted on clinical data of 20 patients (20 eyes) who were diagnosed with ICNV and received intravitreal injection of 0.05 mL (0.5 mg) Conbercept from June 2015 to October 2017 in our hospital.All patients received 1+PRN treatment strategy.The first follow-up was taken 1 week after the first injection,followed by follow-up monthly for 6 months.CNV lesion leakage,best-corrected visual acuity (BCVA),central retinal thickness (CRT),ocular and systemic adverse reactions were recorded.Results All the 20 eyes were given intravitreal Conbercept for one to three times (1.60±0.68),including one time in 10 eyes,two times in 8 eyes and three times in 2 eyes.BCVA was (55.15±6.82)letters before treatment,(61.50±6.16)letters,(71.00±5.10)letters,(73.90±6.75)letters and (77.95±5.12)letters at 1 week,1 month,3 months and 6 months follow-up,respectively.CRT was (342.75±36.39)μm before treatment,(301.15±32.16)μm,(231.85±30.25)μm,(240.05±56.99)μm and (229.75±48.18)μm at 1 week,1 month,3 months and 6 months follow-up.Statistical differences were found in BCVA and CRT at each time points after treatment comparing with that before treatment respetively(all P<0.05).At 6 months follow-up,fluorescein leakage disappeared in 17 eyes,fluorescein leakage area decreased in 3 eyes and no new lesions were found in 20 eyes.During the follow-up,no serious ocular or systemic adverse reactions including glaucoma,intraocular infection,cataract progression,retinal detachment occurred in all 20 eyes.Conclusion Intravitreal Conbercept is a safe and effective treatment for ICNV.

参考文献/References:

[1] 廖菊生.中心性渗出性脉络膜视网膜病变[M]//李凤鸣.眼科全书.北京:人民卫生出版社,1996:3.
LIAO J S.Central exudative chorioretinophy[M]//LI F M.Encyclopedia of ophthalmology.Beijing:People’s Health Publishing House,1996:3.
[2] 刘爱琴,宋子宣.改良视网膜光凝术治疗糖尿病视网膜病变的效果及其对血清血管内皮生长因子和内皮素-1水平的影响[J].新乡医学院学报,2019,36(4):372-375.
LIU A Q,SONG Z X.Effect of modified retinal photocoagulation on diabetic retinopathy and its effect on serum vascular endothelial growth factor and endothelin 1 levels[J].Xinxiang Med Univ,2019,36(4):372-375.
[3] 刘华,许多,陈艳丽,喻红,陈侠,叶剑.康柏西普治疗息肉状脉络膜血管病变的临床疗效[J].眼科新进展,2018,38(12):1144-1147.
LIU H,XU D,CHEN Y L,YU H,CHEN X,YE J.Clinical efficacy of conbercept in the treatment of polypoidal choroidal vasculopathy[J].Rec Adv Ophthalmol,2018,38(12):1144-1147.
[4] 张美霞,严密,唐健,张军军,韦纯义,孟丹.光动力疗法治疗中心性渗出性脉络膜视网膜病变疗效观察[J].中华眼底病杂志,2007,23(1):17-20.
ZHANG M X,YAN M,TANG J,ZHANG J J,WEI C Y,MENG D.Therapeutic effect of photodynamic therapy on central exudative chorioretinopathy[J].Chin J Ocul Fundus Dis,2007,23(1):17-20.
[5] LAI C M,SPILSBURY K,BRANKOV M,ZAKNICH T,RAKOCZY P E.Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA[J].Exp Eye Res,2002,75(6):625-634.
[6] YANG F,DOU H L,MA Z,LI Y L,LU X R,HE P P,et al.Serum inflammatory factors in patients with idiopathic choroidal neovas-cularization[J].Ocul Immunol Inflamm,2010,18(5):390-394.
[7] ADAMIS A P,SHIMA D T.The role of vascular endothelial growth factor in ocular health and disease[J].Retina,2005,25(2):111-118.
[8] KANEKO Y,KITAZATO K,BASAKI Y.Integrin-linked kinase regulates vascular morphogenesis induced by vascular endothelial growth factor[J].J Cell Sci,2004,117(3):407-415.
[9] ZHANG M,ZHANG J,YAN M,LI H,YANG C,YU D.Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovascularization in monkeys[J].Mol Vis,2008,14:37-49.
[10] ZHANG M,YU D C,YANG C,XIA Q J,LI W,LIU B,et al.The pharmacology study of a new recombinant human VEGF receptor-Fc fusion protein on experimental choroidal neovascularization[J].Pharm Res,2009,26(1):204-210.
[11] LI X X,XU G Z,WANG Y S,XU X,LIU X L,TANG S B,et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration:results from a 12-month randomized phase 2 study:AURORA study[J].Ophthalmology,2014,121 (9):1740-1747.
[12] LEI B,XU X,SONG Y.Conbercept for treatment of wet age-related macular degeneration(AMD)[D].Switzerland:ISOPT Symposium Secretariat,2014.
[13] SCHMIDT-ERFURTH U,CHONG V,LOEWENSTEIN A,LARSEN M,SOUIED E,SCHLINGEMANN R,et al.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists(EURETINA)[J].Br J Ophthalmol,2014,98(9):1144-1167.
[14] 路航,崔碌琳,董辉,骆滨江,修巍威,李慧美.康柏西普治疗湿性年龄相关性黄斑变性的临床疗效观察[J].中华眼科杂志,2015,51(11):818-821.
LU H,CUI L L,DONG H,LUO B J,XIU W W,LI H M.Clinical observation of a new anti-VEGF drugs conbercept for wet age-related macular degeneration[J].Chin J Ophthalmol,2015,51(11):818-821.
[15] 焦明菲,李筱荣.康柏西普玻璃体腔注射治疗高度近视脉络膜新生血管的临床疗效及安全性分析[J].中华实验眼科杂志,2016,34(8):725-728.
JIAO M F,LI X R.Clinical safety and efficacy of conbercept intravitreal injection on high myopic choroidal neovascularization[J].Chin J Exp Ophthalmol,2016,34(8):725-728.

相似文献/References:

[1]田蓉 陈有信.特发性脉络膜新生血管的治疗[J].眼科新进展,2012,32(8):000.
[2]张娣,张玲,杨静,等.玻璃体内注射康柏西普联合手术及全视网膜光凝治疗新生血管性青光眼[J].眼科新进展,2015,35(12):1170.[doi:10.13389/j.cnki.rao.2015.0320]
 ZHANG Di,ZHANG Ling,YANG Jing,et al.Intravitreal injection of conbercept combined with operation and panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(1):1170.[doi:10.13389/j.cnki.rao.2015.0320]
[3]李娜,张杰,高荣玉,等.单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化[J].眼科新进展,2016,36(2):172.[doi:10.13389/j.cnki.rao.2016.0047]
 LI Na,ZHANG Jie,GAO Rong-Yu,et al.Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept[J].Recent Advances in Ophthalmology,2016,36(1):172.[doi:10.13389/j.cnki.rao.2016.0047]
[4]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
 WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(1):471.[doi:10.13389/j.cnki.rao.2016.0126]
[5]赵善瑶,姜涛,翟改霞,等.玻璃体内注射雷珠单抗治疗特发性脉络膜新生血管疗效观察[J].眼科新进展,2016,36(6):576.[doi:10.13389/j.cnki.rao.2016.0153]
 ZHAO Shan-Yao,JIANG Tao,ZHAI Gai-Xia,et al.Intravitreal injection of ranibizumab for idiopathic choroidal neovascularization[J].Recent Advances in Ophthalmology,2016,36(1):576.[doi:10.13389/j.cnki.rao.2016.0153]
[6]王玮,徐玲娟,蔡苏博,等.角膜基质及结膜下单次注射康柏西普治疗角膜新生血管的疗效及安全性[J].眼科新进展,2016,36(8):725.[doi:10.13389/j.cnki.rao.2016.0192]
 WANG Wei,XU Lin-Juan,CAI Su-Bo,et al.Efficacy and safety of one dose intrastromal and subconjunctival conbercept injection for corneal neovascularization[J].Recent Advances in Ophthalmology,2016,36(1):725.[doi:10.13389/j.cnki.rao.2016.0192]
[7]史志洁,张金嵩,吕晓贝.玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼[J].眼科新进展,2016,36(8):751.[doi:10.13389/j.cnki.rao.2016.0200]
 SHI Zhi-Jie,ZHANG Jin-Song,LV Xiao-Bei.Intravitreal injection of conbercept and surgical treatment for neovascular glaucoma combined with vitreous hemorrhage[J].Recent Advances in Ophthalmology,2016,36(1):751.[doi:10.13389/j.cnki.rao.2016.0200]
[8]罗顺利,许泽广,梁春正.复合式小梁切除术联合康柏西普治疗新生血管性青光眼[J].眼科新进展,2016,36(11):1076.[doi:10.13389/j.cnki.rao.2016.0287]
 LUO Shun-Li,XU Ze-Guang,LIANG Chun-Zheng.Compound trabeculectomy with conbercept for neovascular glaucoma[J].Recent Advances in Ophthalmology,2016,36(1):1076.[doi:10.13389/j.cnki.rao.2016.0287]
[9]吴若欣,徐洁慧,温积全,等.玻璃体内注射康柏西普对渗出性老年性黄斑变性患者脉络膜厚度的影响[J].眼科新进展,2016,36(12):1172.[doi:10.13389/j.cnki.rao.2016.0312]
 WU Ruo-Xin,XU Jie-Hui,WEN Ji-Quan,et al.Effects of intravitreal conbercept injections on choroidal thickness in exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2016,36(1):1172.[doi:10.13389/j.cnki.rao.2016.0312]
[10]薛鹏程,游志鹏,付书华,等.23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普治疗增生型糖尿病视网膜病变(PDR)的疗效分析[J].眼科新进展,2017,37(5):458.[doi:10.13389/j.cnki.rao.2017.0116]
 XUE Peng-Cheng,YOU Zhi-Peng,FU Shu-Hua,et al.Preoperative and intraoperative adjunctive intravitreal conbercept in 23G vitrectomy for proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2017,37(1):458.[doi:10.13389/j.cnki.rao.2017.0116]
[11]郑元建,韩慧,朱月莹.玻璃体内注射雷珠单抗与康柏西普治疗特发性脉络膜新生血管的临床疗效对比[J].眼科新进展,2020,40(2):177.[doi:10.13389/j.cnki.rao.2020.0042]
 ZHENG Yuanjian,HAN Hui,ZHU Yueying.Comparative study on clinical efficacy between intravitreal injection of Ranibizumab and Conbercept in treatment of idiopathic choroidal neovascularization[J].Recent Advances in Ophthalmology,2020,40(1):177.[doi:10.13389/j.cnki.rao.2020.0042]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2020-01-05